|
Models of Infectious Disease Agent Study (MIDAS)
|
Research Initiative
|
CDC
|
NIGMS, FIC, NIAID
|
Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems, and response strategies. The models will be useful to public health workers and researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid in our understanding of the disease and its spread.
|
|
Modernizing the Infrastructure for Capturing Drug Death Data and Enhancing Research on Opioid Poisoning using Death Certificates
|
Resource Development
|
CDC
|
NLM
|
(1) Advising the National Center for Health Statistics (NCHS) on strategies to extract, categorize and map drug-related strings terms and phrases from death certificate records’ literal text to classification systems used by researchers. (2) Establishing mappings between information technology systems that assure classification standards are used with respect to clinical terminologies. (3) Developing natural language processing (NLP) programs that reduce manual processes in classifying new drug terms identified on death certificates.
|
|
Monthly Value Based Transformation Calls
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, BARDA, CDC, CMS, IHS
|
NIGMS, NHLBI, NIAID, NICHD
|
To exchange information on sepsis initiatives and priorities particularly as related to the Department of Health and Human Services (HHS) Secretary’s Value Based Transformation initiative, to promote communication and coordination between agencies that support sepsis research and impact/influences sepsis treatment.
|
|
Monthly Zika Vaccine Development Meeting
|
Resource Development
|
BARDA, FDA
|
NIAID
|
This working group is collaborating on development of assays and animal models for zika vaccines. Collaboration includes exchange of study data, study reports, and regulatory strategy for assay and model development and development of a regulatory package to support licensure of products through alternative pathways.
|
|
Multinational Influenza Seasonal Mortality Study (MISMS) Research
|
Research Initiative
|
FDA, OS
|
FIC, NHLBI, NIAID, NLM
|
The Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses, on natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications.
|
|
Muscular Dystrophy Coordinating Committee (MDCC)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CDC, FDA, HRSA
|
NINDS, NHLBI, NIAMS, NICHD
|
This Federal Advisory Committee coordinates activities relevant to the various forms of muscular dystrophy across the National Institutes of Health (NIH) and other federal agencies. The committee also includes members from patient organizations. Strategic planning efforts by the coordinating committee led to the development of an Action Plan for the Muscular Dystrophies, which contains specific research objectives appropriate to the missions of all committee member agencies and organizations, and thus serves as a central focus for research coordination. The plan is available at the MDCC web site.
|
|
My Family Health Portrait
|
Resource Development
|
CDC
|
NHGRI, NCI
|
My Family Health Portrait (MFHP) is a web-based tool from the National Human Genome Research Institute (NHGRI) and the US Surgeon General’s Family History Initiative that helps individuals track their family health history. Using any computer, an Internet connection, and an up-to-date Web browser, individuals add health information to build a drawing of their family tree and a chart of their family health history while exploring disease calculators. The tool is designed to keep all data on the client side to maximize privacy using HTML, CSS, and client-side JavaScript as its principal platforms. Users interact with the tool in a browser to build family health history generating an XML data file (HL7v3 standard) that users store locally or in the cloud. Both the family tree and the chart can be printed and shared with family members and an individual’s doctor.
|
|
Nanotechnology Characterization Laboratory
|
Research Initiative
|
FDA
|
NCI, NIEHS
|
The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications.
|
|
National Action Alliance for Suicide Prevention (NAASP)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CDC, HRSA, IHS, OS, OSG, SAMHSA
|
NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP
|
Founded in September 2010, the NAASP is a public-private partnership designed to advance the National Strategy for Suicide Prevention in the United States. The NAASP''s Research Prioritization Task Force (RPTF) was charged with developing a process to prioritize suicide prevention research efforts and consider ways to integrate science and service to ensure that suicide deaths decrease significantly within the next decade. The RPTF released the Nation''s first suicide research agenda, A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. The research agenda includes an overarching goal to advance suicide prevention research more rapidly, seeking ways to reduce suicide deaths and attempts by 20 percent in five years and by 40 percent or greater in ten years. In 2015, the RPTF produced the "U.S. National Suicide Prevention Research Efforts: 2008-2013 Portfolio Analyses." The analyses revealed that investments in suicide research are severely lagging, but there is a growing knowledge base of intervention research. The NIMH Director serves as an ex-officio member of the Executive Committee of the NAASP. NIMH participates in a number of NAASP activities related to identifying research needs for improving risk identification and suicide preventive care within healthcare systems, justice and school settings.
|
|
NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA (CARB) 2020-2025
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS
|
NIAID
|
The National Action Plan for Combating Antibiotic-resistant Bacteria, 2020-2025, in development through the CARB Task Force, will outline coordinated, strategic actions that the U.S. government will take in the next five years to reduce the impact of antibiotic and antimicrobial resistance on the nation.
|